Publications
- 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group2013 | Central Library of Charles University
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial +12012 | First Faculty of Medicine
- 2.3.2. G-CSF, Growth factor for granulocytic series2012 | First Faculty of Medicine
- An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation2011 | First Faculty of Medicine
- Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial2010 | First Faculty of Medicine
- Autologous stem cell transplantation for AL amyloidosis –single-center results of a strict risk-adapted approach.2010 | First Faculty of Medicine
- Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre2010 | First Faculty of Medicine
- Autologous transplantation in 495 multiple myeloma patients - Analysis from the Czech National Registry of Hematopoietic Stem Cell Transplantation2007 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
Loading network view...